Harvard Bioscience, Inc. (NASDAQ:HBIO) Short Interest Update

Harvard Bioscience, Inc. (NASDAQ:HBIO) was the target of a significant growth in short interest in the month of February. As of February 15th, there was short interest totalling 906,600 shares, a growth of 19.5% from the January 31st total of 758,600 shares. Based on an average daily volume of 240,800 shares, the days-to-cover ratio is presently 3.8 days. Currently, 2.4% of the company’s stock are sold short.

Institutional Trading of Harvard Bioscience

Several hedge funds have recently made changes to their positions in HBIO. JPMorgan Chase & Co. raised its holdings in Harvard Bioscience by 63.0% during the third quarter. JPMorgan Chase & Co. now owns 29,501 shares of the medical instruments supplier’s stock worth $79,000 after purchasing an additional 11,397 shares in the last quarter. Barclays PLC boosted its position in shares of Harvard Bioscience by 304.4% in the third quarter. Barclays PLC now owns 58,655 shares of the medical instruments supplier’s stock worth $157,000 after buying an additional 44,150 shares during the period. State Street Corp boosted its position in Harvard Bioscience by 1.1% during the 3rd quarter. State Street Corp now owns 717,387 shares of the medical instruments supplier’s stock worth $1,930,000 after acquiring an additional 7,763 shares during the period. Geode Capital Management LLC lifted its position in Harvard Bioscience by 2.2% in the 3rd quarter. Geode Capital Management LLC now owns 912,599 shares of the medical instruments supplier’s stock worth $2,455,000 after buying an additional 19,972 shares in the last quarter. Finally, Bard Associates Inc. raised its holdings in shares of Harvard Bioscience by 5.2% during the third quarter. Bard Associates Inc. now owns 312,399 shares of the medical instruments supplier’s stock worth $840,000 after acquiring an additional 15,404 shares in the last quarter. Institutional investors own 80.87% of the company’s stock.

Harvard Bioscience Stock Performance

Harvard Bioscience stock opened at $0.82 on Friday. Harvard Bioscience has a 52 week low of $0.78 and a 52 week high of $4.70. The company has a current ratio of 2.06, a quick ratio of 0.91 and a debt-to-equity ratio of 0.52. The stock has a market cap of $35.71 million, a P/E ratio of -2.48 and a beta of 1.25. The stock has a 50 day moving average of $1.56 and a 200-day moving average of $2.15.

About Harvard Bioscience

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.